# Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

> **NCT02504359** · PHASE1 · COMPLETED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 11 (actual)

## Conditions studied

- Plasma Cell Leukemia
- Recurrent Plasma Cell Myeloma

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Carmustine
- **DRUG:** Cytarabine
- **DRUG:** Etoposide
- **DRUG:** Ixazomib Citrate
- **DRUG:** Melphalan
- **DRUG:** Methotrexate
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT02504359
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-20
- **Primary completion:** 2020-09-09
- **Final completion:** 2020-09-09
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2020-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02504359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02504359, "Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02504359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*